FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885149454> ?p ?o ?g. }

• W2885149454 endingPage "e1018" @default.
• W2885149454 startingPage "e1008" @default.
• W2885149454 abstract "BackgroundAngiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), β blockers, and mineralocorticoid receptor antagonists (MRAs) are of proven benefit and are recommended by guidelines for management of patients with heart failure and reduced ejection fraction (HFrEF). We aimed to examine the first prospective multinational data from Asia on prescribing patterns of guideline-directed medical therapies and analyse its effect on outcomes.MethodsIn the prospective multinational ASIAN-HF registry (with enrolment from 46 centres in 11 countries in Asia), we enrolled patients aged 18 years or older, with symptomatic heart failure (stage C, with at least one episode of decompensated heart failure in the past 6 months that resulted in admission to hospital or was treated in an outpatient clinic) and left ventricular systolic dysfunction (ejection fraction ≤40% on baseline echocardiography, consistent with 2016 European Society of Cardiology guidelines). We excluded patients with heart failure caused by severe valvular heart disease, life-threatening comorbidity with a life expectancy of less than 1 year, who were unable or unwilling to give consent, or who had concurrent participation in a clinical trial. Patients were followed up for 3 years for the outcomes of death and cause-specific admittance to hospital. Primary outcomes were uptake of guideline-directed medical therapies (as proportions) by therapeutic class, achieved doses as proportions of guideline-recommended doses, and their association with 1-year composite outcome of all-cause death or admittance to hospital because of heart failure. This study is registered with ClinicalTrials.gov, number NCT01633398.FindingsBetween Oct 1, 2012, and Dec 31, 2015, we enrolled 5276 patients with HFrEF (mean age 59·6 years [SD 13·2], 77% men, body-mass index 24·9 kg/m2 [5·1], 33% New York Heart Association class III or IV). Follow-up data were available for 4544 (90%) of 5061 eligible patients taking medication for heart failure, with median follow-up of 417 days (IQR 214–735). ACE inhibitors or ARBs were prescribed to 3868 (77%) of 5005 patients, β blockers to 3975 (79%) of 5061, and MRAs to 2998 (58%) of 5205, with substantial regional variation. Guideline-recommended dose was achieved in only 17% of cases for ACE inhibitors or ARB, 13% for β blockers, and 29% for MRAs. Country (all three drug classes), increasing body-mass index (ACE inhibitors or ARBs and MRAs), and in-patient recruitment (ACE inhibitors or ARBs and β blockers) were associated with attainment of guideline-recommended dose (all p<0·05). When adjusted for indication bias, increasing drug doses, from low dose (1–<25% of guideline-recommended dose) upwards were associated with lower hazards of a 1-year composite outcome for ACE inhibitors or ARBs and β blockers compared with non-users. The lowest adjusted hazards were in the group that attained guideline-recommended doses above 50% (hazard ratio [HR] 0·54, 95% CI 0·50–0·58 for ACE inhibitors or ARBs [50–99·9%]; HR 0·47, 0·46–0·50 for β blockers, and HR 0·77, 0·72–0·81 for MRAs [≥100%]).InterpretationGuideline-directed medical therapies at recommended doses are underutilised in patients with HFrEF. Improved uptake and uptitration of guideline-directed medical therapies are needed for better patient outcomes.FundingNational Medical Research Council (Singapore), A*STAR Biomedical Research Council ATTRaCT program, Boston Scientific Investigator Sponsored Research program, and Bayer." @default.
• W2885149454 created "2018-08-22" @default.
• W2885149454 creator A5000397430 @default.
• W2885149454 creator A5010491253 @default.
• W2885149454 creator A5019267804 @default.
• W2885149454 creator A5023104782 @default.
• W2885149454 creator A5027486335 @default.
• W2885149454 creator A5031262573 @default.
• W2885149454 creator A5034293877 @default.
• W2885149454 creator A5039835238 @default.
• W2885149454 creator A5043224002 @default.
• W2885149454 creator A5070392454 @default.
• W2885149454 creator A5074566771 @default.
• W2885149454 creator A5075734108 @default.
• W2885149454 creator A5075949562 @default.
• W2885149454 creator A5086850743 @default.
• W2885149454 creator A5090527958 @default.
• W2885149454 date "2018-09-01" @default.
• W2885149454 modified "2023-10-17" @default.
• W2885149454 title "Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study" @default.
• W2885149454 cites W1921362862 @default.
• W2885149454 cites W1969727819 @default.
• W2885149454 cites W1970930841 @default.
• W2885149454 cites W1972869125 @default.
• W2885149454 cites W1994016751 @default.
• W2885149454 cites W2008706768 @default.
• W2885149454 cites W2033024867 @default.
• W2885149454 cites W2037668591 @default.
• W2885149454 cites W2055457865 @default.
• W2885149454 cites W2081375534 @default.
• W2885149454 cites W2088864613 @default.
• W2885149454 cites W2090124984 @default.
• W2885149454 cites W2098194481 @default.
• W2885149454 cites W2105138814 @default.
• W2885149454 cites W2115098571 @default.
• W2885149454 cites W2129711762 @default.
• W2885149454 cites W2139888542 @default.
• W2885149454 cites W2163134559 @default.
• W2885149454 cites W2170674956 @default.
• W2885149454 cites W2312186855 @default.
• W2885149454 cites W2323458614 @default.
• W2885149454 cites W2342809951 @default.
• W2885149454 cites W2427094903 @default.
• W2885149454 cites W2506287656 @default.
• W2885149454 cites W2592176942 @default.
• W2885149454 cites W2611250527 @default.
• W2885149454 cites W2925654603 @default.
• W2885149454 cites W4238907867 @default.
• W2885149454 cites W4252322944 @default.
• W2885149454 cites W4294541781 @default.
• W2885149454 cites W2041385898 @default.
• W2885149454 doi "https://doi.org/10.1016/s2214-109x(18)30306-1" @default.
• W2885149454 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30103979" @default.
• W2885149454 hasPublicationYear "2018" @default.
• W2885149454 type Work @default.
• W2885149454 sameAs 2885149454 @default.
• W2885149454 citedByCount "102" @default.
• W2885149454 countsByYear W28851494542018 @default.
• W2885149454 countsByYear W28851494542019 @default.
• W2885149454 countsByYear W28851494542020 @default.
• W2885149454 countsByYear W28851494542021 @default.
• W2885149454 countsByYear W28851494542022 @default.
• W2885149454 countsByYear W28851494542023 @default.
• W2885149454 crossrefType "journal-article" @default.
• W2885149454 hasAuthorship W2885149454A5000397430 @default.
• W2885149454 hasAuthorship W2885149454A5010491253 @default.
• W2885149454 hasAuthorship W2885149454A5019267804 @default.
• W2885149454 hasAuthorship W2885149454A5023104782 @default.
• W2885149454 hasAuthorship W2885149454A5027486335 @default.
• W2885149454 hasAuthorship W2885149454A5031262573 @default.
• W2885149454 hasAuthorship W2885149454A5034293877 @default.
• W2885149454 hasAuthorship W2885149454A5039835238 @default.
• W2885149454 hasAuthorship W2885149454A5043224002 @default.
• W2885149454 hasAuthorship W2885149454A5070392454 @default.
• W2885149454 hasAuthorship W2885149454A5074566771 @default.
• W2885149454 hasAuthorship W2885149454A5075734108 @default.
• W2885149454 hasAuthorship W2885149454A5075949562 @default.
• W2885149454 hasAuthorship W2885149454A5086850743 @default.
• W2885149454 hasAuthorship W2885149454A5090527958 @default.
• W2885149454 hasBestOaLocation W28851494541 @default.
• W2885149454 hasConcept C126322002 @default.
• W2885149454 hasConcept C142724271 @default.
• W2885149454 hasConcept C164705383 @default.
• W2885149454 hasConcept C177713679 @default.
• W2885149454 hasConcept C188816634 @default.
• W2885149454 hasConcept C194828623 @default.
• W2885149454 hasConcept C2778198053 @default.
• W2885149454 hasConcept C2779159551 @default.
• W2885149454 hasConcept C2780182762 @default.
• W2885149454 hasConcept C71924100 @default.
• W2885149454 hasConcept C78085059 @default.
• W2885149454 hasConceptScore W2885149454C126322002 @default.
• W2885149454 hasConceptScore W2885149454C142724271 @default.
• W2885149454 hasConceptScore W2885149454C164705383 @default.
• W2885149454 hasConceptScore W2885149454C177713679 @default.
• W2885149454 hasConceptScore W2885149454C188816634 @default.
• W2885149454 hasConceptScore W2885149454C194828623 @default.
• W2885149454 hasConceptScore W2885149454C2778198053 @default.

• next